Eli Lilly and Company (NYSE:LLY) Shares Down 0%

Eli Lilly and Company (NYSE:LLY)’s stock price traded down 0% during trading on Wednesday . The company traded as low as $767.38 and last traded at $774.61. 685,312 shares changed hands during trading, a decline of 79% from the average session volume of 3,209,096 shares. The stock had previously closed at $774.90.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Bank of America increased their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Barclays increased their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Morgan Stanley increased their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, Truist Financial restated a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $689.52.

Eli Lilly and Company Stock Up 0.1 %

The firm’s 50-day simple moving average is $725.15 and its 200 day simple moving average is $634.68. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a market capitalization of $737.20 billion, a P/E ratio of 133.55, a PEG ratio of 1.70 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter in the prior year, the business earned $2.09 EPS. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, research analysts expect that Eli Lilly and Company will post 12.42 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 14,388 shares of the company’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $630.28, for a total transaction of $9,068,468.64. Following the completion of the sale, the insider now owns 99,754,422 shares of the company’s stock, valued at approximately $62,873,217,098.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 195,055 shares of company stock worth $125,254,657 in the last quarter. Corporate insiders own 0.13% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently bought and sold shares of LLY. Lipe & Dalton bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Retirement Group LLC increased its holdings in Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares during the period. Tidemark LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter worth $29,000. Finally, Core Wealth Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.